NCT04302519 is a EARLY_PHASE1 clinical trial of Dental pulp mesenchymal stem cells in COVID-19, sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd..

Who is sponsoring NCT04302519?

NCT04302519 is sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd..

What drugs are being tested in NCT04302519?

Interventions in NCT04302519: Dental pulp mesenchymal stem cells.

Is NCT04302519 still recruiting?

NCT04302519 is currently status unknown. Last updated 10 March 2020.

Last reviewed 2020-03-10 · How we verify

NCT04302519

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Novel Coronavirus Induced Severe Pneumonia Treated by Dental Pulp Mesenchymal Stem Cells

Status unknown EARLY_PHASE1 Last updated 10 March 2020

What this trial tests

EARLY_PHASE1 trial testing Dental pulp mesenchymal stem cells in COVID-19 in 24 participants. Status unknown.

Timeline

5 March 2020

Primary endpoint
30 June 2021

30 July 2021

Quick facts

Lead sponsor	CAR-T (Shanghai) Biotechnology Co., Ltd.
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	24
Start date	5 March 2020
Primary completion	30 June 2021
Estimated completion	30 July 2021

Drugs / interventions tested

Dental pulp mesenchymal stem cells — full drug profile →

Conditions studied

COVID-19 — all drugs for COVID-19 →

Sponsor

CAR-T (Shanghai) Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Evaluation of novel coronavirus induced severe pneumonia by dental pulp mesenchymal stem cells

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Challenges and advances in clinical applications of mesenchymal stromal cells.
Zhou T, Yuan Z, Weng J, Pei D, et al · · 2021 · cited 489× · PMID 33579329 · DOI 10.1186/s13045-021-01037-x
COVID-19: Transmission, prevention, and potential therapeutic opportunities.
Lotfi M, Hamblin MR, Rezaei N. · · 2020 · cited 447× · PMID 32474009 · DOI 10.1016/j.cca.2020.05.044
A Review of SARS-CoV-2 and the Ongoing Clinical Trials.
Tu YF, Chien CS, Yarmishyn AA, Lin YY, et al · · 2020 · cited 406× · PMID 32290293 · DOI 10.3390/ijms21072657
Ongoing Clinical Trials for the Management of the COVID-19 Pandemic.
Lythgoe MP, Middleton P. · · 2020 · cited 247× · PMID 32291112 · DOI 10.1016/j.tips.2020.03.006
Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.
Golchin A, Seyedjafari E, Ardeshirylajimi A. · · 2020 · cited 221× · PMID 32281052 · DOI 10.1007/s12015-020-09973-w
COVID-19 and Cancer: a Comprehensive Review.
Gosain R, Abdou Y, Singh A, Rana N, et al · · 2020 · cited 187× · PMID 32385672 · DOI 10.1007/s11912-020-00934-7
Combating COVID-19 with mesenchymal stem cell therapy.
Rajarshi K, Chatterjee A, Ray S. · · 2020 · cited 65× · PMID 32420049 · DOI 10.1016/j.btre.2020.e00467
Immunobiology and immunotherapy of COVID-19: A clinically updated overview.
Esmaeilzadeh A, Elahi R. · · 2021 · cited 59× · PMID 33022076 · DOI 10.1002/jcp.30076

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other CAR-T (Shanghai) Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT05127369 — Clinical Study on the Safety and Efficacy of Dental Pulp Mesenchymal Cells in the Treatment of Depression · NA · unknown
NCT04130100 — Clinical Study of Pulp Mesenchymal Stem Cells in the Treatment of Primary Mild to Moderate Knee Osteoarthritis · EARLY_PHASE1 · unknown
NCT03912480 — Stem Cells From Human Exfoliated Teeth in Treatment of Diabetic Patients With Significantly Reduced Islet Function · EARLY_PHASE1 · unknown
NCT03658655 — Stem Cells From Human Exfoliated Teeth in Treatment of Type 2 Diabetes · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04302519 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CAR-T (Shanghai) Biotechnology Co., Ltd.
Last refreshed: 10 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04302519.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing